IV Paracetamol Reduces Morphine Use in Young Children Post-Cardiac Surgery, reveals research

Written By :  Dr Riya Dave
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-05-31 14:45 GMT   |   Update On 2024-06-01 06:02 GMT

Researchers have found that intermittent intravenous (IV) paracetamol significantly reduces morphine consumption in young children undergoing cardiac surgery with cardiopulmonary bypass. This multicenter, randomized, double-blind, controlled trial conducted in Pediatric Intensive Care Units (PICUs) across the Netherlands and Belgium, assessed the effectiveness of IV paracetamol as the primary analgesic option compared to continuous morphine use. The study was published in the journal Critical Care by Gerdien Zeilmaker-Roest and colleagues.

Advertisement

Morphine has traditionally been used for pain management in children undergoing cardiac surgery, but it comes with risks such as respiratory depression. Paracetamol is a potential alternative to reduce these risks while still providing effective pain management.

The study included 194 patients aged 0-3 years who underwent cardiac surgery with cardiopulmonary bypass between March 2016 and July 2020. Patients were randomized to either continuous morphine or intermittent IV paracetamol as the primary analgesic after receiving a loading dose of 100 mcg/kg of morphine at the end of surgery. Rescue morphine was administered if numeric rating scale (NRS) pain scores exceeded a predetermined threshold.

The primary outcome was the median weight-adjusted cumulative morphine dose (mcg/kg) in the first 48 hours post-surgery. The study used the nonparametric Van Elteren test, stratified by center, for primary outcome comparison.

The key findings of the study were:

• The IV paracetamol group had a median weight-adjusted cumulative morphine dose of 145.0 mcg/kg (IQR 115.0-432.5 mcg/kg) compared to 692.6 mcg/kg (IQR 532.7-856.1 mcg/kg) in the continuous morphine group.

• This represents a 79% reduction in morphine use (P < 0.001).

• Both groups showed similar rescue morphine consumption (P = 0.38) and similar levels of pain relief, suggesting non-inferiority of IV paracetamol administration in terms of NRS pain scores.

• The non-inferiority analysis revealed a difference in proportion of patients with NRS pain scores of 4 or higher between the groups at -3.1% (95% CI -16.6-10.3%).

These findings suggest that IV paracetamol is an effective primary analgesic option for children aged 0-3 years post-cardiac surgery, offering significant reductions in morphine use without compromising pain relief. This could be a safer and potentially more efficient approach to post-surgical pain management.

The use of intermittent IV paracetamol as the primary analgesic in children aged 0-3 years after cardiac surgery with cardiopulmonary bypass results in a significant 79% reduction in median weight-adjusted cumulative morphine consumption over the first 48 hours post-surgery. The findings suggest that IV paracetamol provides equal pain relief compared to continuous morphine, indicating its potential as a safer and effective primary analgesic option for young children post-cardiac surgery.

Reference:

Zeilmaker-Roest, G., de Vries-Rink, C., van Rosmalen, J., van Dijk, M., de Wildt, S. N., Knibbe, C. A. J., Koomen, E., Jansen, N. J. G., Kneyber, M. C. J., Maebe, S., Van den Berghe, G., Haghedooren, R., Vlasselaers, D., Bogers, A. J. J. C., Tibboel, D., & Wildschut, E. D. (2024). Intermittent intravenous paracetamol versus continuous morphine in infants undergoing cardiothoracic surgery: a multi-center randomized controlled trial. Critical Care (London, England), 28(1). https://doi.org/10.1186/s13054-024-04905-3

Tags:    
Article Source : Critical Care

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News